Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury

American Journal of Transplantation

Volumn 7, Issue 1, 2007, Pages 218-225

  Baskin Bey, E S ^a   Washburn, K ^b   Feng, S ^c   Oltersdorf, T ^d   Shapiro, D ^d   Huyghe, MiRa ^d   Burgart, L ^a   Garrity Park, M ^a   Van Vilsteren, F G I ^a   Oliver, L K ^a   Rosen, C B ^a   Gores, G J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PFIZER INC   (United States)

Author keywords

Apoptosis; Clinical trial; Cold ischemia warm reperfusion injury; Neutrophil infiltration

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ASPARTIC ACID; BIOLOGICAL MARKER; CASPASE 3; CASPASE 7; CYSTEINE PROTEINASE INHIBITOR; EPITOPE; MYCOPHENOLIC ACID; PLACEBO; PREDNISONE; TACROLIMUS;

ADULT; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANXIETY; APOPTOSIS; ARTERY OCCLUSION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT OBSTRUCTION; BILIARY TRACT DISEASE; BLOOD DYSCRASIA; BRADYCARDIA; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFUSION; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRYOPRESERVATION; DEATH; DEPRESSION; DIPLOPIA; DOUBLE BLIND PROCEDURE; ENZYME ASSAY; FEMALE; GRAFT DYSFUNCTION; HEART ATRIUM FIBRILLATION; HEART BUNDLE BRANCH BLOCK; HEART DISEASE; HEART FUNCTION; HEPATIC ARTERY STENOSIS; HEPATITIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISCHEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER CELL; LIVER GRAFT REJECTION; LIVER INJURY; LIVER PRESERVATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTICENTER STUDY; NEUROLOGICAL COMPLICATION; NEUTROPHIL CHEMOTAXIS; NICK END LABELING; ORGAN PRESERVATION; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; RETRANSPLANTATION; SEIZURE; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA;

ADULT; APOPTOSIS; CASPASES; ENZYME TESTS; FEMALE; HUMANS; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PENTANOIC ACIDS; PROTECTIVE AGENTS; REPERFUSION INJURY; TRANSAMINASES;

EID: 33845654847     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01595.x     Document Type: Article

References (30)

1. Fellstrom B, Akuyrek LM, Backman U, Larsson E, Melin J, Zezina L. Postischemic reperfusion injury and allograft arteriosclerosis. Transplant Proc 1998; 30: 4278-4280.
2. Belzer FO, Southard JH. Principles of solid-organ preservation by cold storage. Transplantation 1988; 45: 673-676.
3. Kang KJ. Mechanism of hepatic ischemia/reperfusion injury and protection against reperfusion injury. Transplant Proc 2002; 34: 2659-2661.
4. Kupiec-Weglinski JW, Busuttil RW. Ischemia and reperfusion injury in liver transplantation. Transplant Proc 2005; 37: 1653-1656.
5. Sindram D, Porte RJ, Hoffman MR, Bentley RC, Clavien PA. Platelets induce sinusoidal endothelial cell apoptosis upon reperfusion of the cold ischemic rat liver. Gastroenterology 2000; 118: 183-191.
6. Kohli V, Selzner M, Madden JF, Bentley RC, Clavien PA. Endothelial cell and hepatocyte deaths occur by apoptosis after ischemia-reperfusion injury in the rat liver. Transplantation 1999; 67: 1099-1105.
7. Kuo PC, Drachenberg CI, de la Torre A et al. Apoptosis and hepatic allograft reperfusion injury. Clin Transplant 1998; 12: 219-223.
8. Borghi-Scoazec G, Scoazec JY, Durand F et al. Apoptosis after ischemia-reperfusion in human liver allografts. Liver Transpl Surg 1997; 3: 407-415.
9. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116: 205-219.
10. Selzner N, Rudiger H, Graf R, Clavien PA. Protective strategies against ischemic injury of the liver. Gastroenterology 2003; 125: 917-936.
11. Rudiger HA, Graf R, Clavien PA. Liver ischemia: Apoptosis as a central mechanism of injury. J Invest Surg 2003; 16: 149-159.
12. Natori S, Selzner M, Valentino KL et al. Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase dependent mechanism. Transplantation 1999; 68: 89-96.
13. Natori S, Higuchi H, Contreras P, Gores GJ. The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. Liver Transpl 2003; 9: 278-284.
14. Linton SD, Aja T, Armstrong RA et al. First-in-class pan caspase inhibitor developed for the treatment of liver disease. J Med Chem 2005; 48: 6779-6782.
15. Valentino KL, Gutierrez M, Sanchez R, Winship MJ, Shapiro DA. First clinical trial of a novel caspase inhibitor: Anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther 2003; 41: 441-449.
16. Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC. Characterization of IDN-6556 (3-[2-(2-tert-butylphenylaminooxalyl)-amino]- propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): A liver-targeted caspase inhibitor. J Pharmacol Exp Ther 2004; 309: 634-640.
17. Quadri SM, Segall L, de Perrot M et al. Caspase inhibition improves ischemia-reperfusion injury after lung transplantation. Am J Transplant 2005; 5: 292-299.
18. Leers MP, Kolgen W, Bjorklund V et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999; 187: 567-572.
19. Schutte B, Henfling M, Kolgen W et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004; 297: 11-26.
20. Hagg M, Biven K, Ueno T et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 2002; 20: 253-259.
21. Garrity MM, Burgart LJ, Riehle DL, Hill EM, Sebo TJ, Witzig T. Identifying and quantifying apoptosis: Navigating technical pitfalls. Mod Pathol 2003; 16: 389-394.
22. Canbay A, Guicciardi ME, Higuchi H et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestatsis. J Clin Invest 2003; 112: 152-159.
23. Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989; 83: 865-875.
24. Alvarado-Kristensson M, Melander F, Leandersson K, Ronnstrand L, Wernstedt C, Andersson T. p38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. J Exp Med 2004; 199: 449-458.
25. Perianayagam MC, Balakrishnan VS, Pereira BJ, Jaber BL. C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and Bad-mediated signalling pathway. Eur J Clin Invest 2004; 34: 50-56.
26. Khreiss T, Jozsef L, Chan JS, Filep JG. Activation of extracellular signal-regulated kinase couples platelet-activating factor-induced adhesion and delayed apoptosis of human neutrophils. Cell Signal 2004; 16: 801-810.
27. Baskin-Bey ES, Canbay A, Bronk SF et al. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2005; 288: G396-G402.
28. Kohli V, Gao W, Camargo CA, Jr., Clavien PA. Calpain is amediator of preservation-reperfusion injury in rat liver transplantation. Proc Natl Acad Sci USA 1997; 94: 9354-9359.
29. Foghsgaard L, Wissing D, Mauch D et al. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol 2001; 153: 999-1010.
30. Clavien PA, Harvey PR, Strasberg SM. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation 1992; 53: 957-978.